These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 18199195)

  • 1. Impact of Medicaid prior authorization requirement for COX-2 inhibitor drugs in Nebraska.
    Siracuse MV; Vuchetich PJ
    Health Serv Res; 2008 Feb; 43(1 Pt 2):435-50. PubMed ID: 18199195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of an automated system for prior authorization: a COX-2 inhibitor example.
    Carroll NV; Smith JC; Berringer RA; Oestreich GL
    Am J Manag Care; 2006 Sep; 12(9):501-8. PubMed ID: 16961439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of a prior-authorization requirement on the use of nonsteroidal antiinflammatory drugs by Medicaid patients.
    Smalley WE; Griffin MR; Fought RL; Sullivan L; Ray WA
    N Engl J Med; 1995 Jun; 332(24):1612-7. PubMed ID: 7753141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors.
    Fischer MA; Schneeweiss S; Avorn J; Solomon DH
    N Engl J Med; 2004 Nov; 351(21):2187-94. PubMed ID: 15548779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effect of early or late implementation of prior authorization policies on the use of Cox II inhibitors.
    Roughead EE; Zhang F; Ross-Degnan D; Soumerai S
    Med Care; 2006 Apr; 44(4):378-82. PubMed ID: 16565640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of selective cyclooxygenase-2 inhibitors on anti-ulcer medication and non-steroidal anti-inflammatory drug use in patients with rheumatic disease.
    Joshua FF; Oakley SP; Major GA
    Intern Med J; 2004 Apr; 34(4):153-61. PubMed ID: 15086694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs.
    Hur C; Chan AT; Tramontano AC; Gazelle GS
    Ann Pharmacother; 2006 Jun; 40(6):1052-63. PubMed ID: 16720709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Underutilization of preventive strategies in patients receiving NSAIDs.
    Sturkenboom MC; Burke TA; Dieleman JP; Tangelder MJ; Lee F; Goldstein JL
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii23-31. PubMed ID: 14585915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonsteroidal antiinflammatory drug use among patients with GI bleeding.
    Dominick KL; Bosworth HB; Jeffreys AS; Grambow SC; Oddone EZ; Horner RD
    Ann Pharmacother; 2004; 38(7-8):1159-64. PubMed ID: 15187205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a prior-authorization policy for celecoxib on medical service and prescription drug use in a managed care Medicaid population.
    Hartung DM; Touchette DR; Ketchum KL; Haxby DG; Goldberg BW
    Clin Ther; 2004 Sep; 26(9):1518-32. PubMed ID: 15531015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prior authorization policies for selective cyclooxygenase-2 inhibitors in Medicaid: a policy review.
    Fischer MA; Cheng H; Schneeweiss S; Avorn J; Solomon DH
    Med Care; 2006 Jul; 44(7):658-63. PubMed ID: 16799360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study.
    Moride Y; Ducruet T; Boivin JF; Moore N; Perreault S; Zhao S
    Arthritis Res Ther; 2005; 7(2):R333-42. PubMed ID: 15743481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs.
    Targownik LE; Metge CJ; Leung S; Chateau DG
    Gastroenterology; 2008 Apr; 134(4):937-44. PubMed ID: 18294634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastrointestinal safety of nonsteroidal antiinflammatory drugs and selective cyclooxygenase-2 inhibitors in patients on warfarin.
    Cheetham TC; Levy G; Niu F; Bixler F
    Ann Pharmacother; 2009 Nov; 43(11):1765-73. PubMed ID: 19809010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
    Scheiman JM; Hindley CE
    Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilization and costs of medical services and prescription medications for rheumatoid arthritis among recipients covered by a state Medicaid program: a retrospective, cross-sectional, descriptive, database analysis.
    Khanna R; Smith MJ
    Clin Ther; 2007 Nov; 29(11):2456-67. PubMed ID: 18158087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in the cost of antidepressants across state Medicaid programs.
    Kelton CM; Rebelein RP; Heaton PC; Ferrand Y; Guo JJ
    J Ment Health Policy Econ; 2008 Mar; 11(1):33-47. PubMed ID: 18424875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of gastrointestinal preventive therapy among elderly persons receiving antiarthritic agents in Nova Scotia, Canada.
    Hartnell NR; Flanagan PS; MacKinnon NJ; Bakowsky VS
    Am J Geriatr Pharmacother; 2004 Sep; 2(3):171-80. PubMed ID: 15561649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy switching and associated costs in elderly patients receiving COX-2 selective inhibitors or non-selective non-steroidal anti-inflammatory drugs in Quebec, Canada.
    Rahme E; Toubouti Y; Hunsche E
    Rheumatology (Oxford); 2006 Jul; 45(7):903-10. PubMed ID: 16461440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
    Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D
    J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.